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Summary
Background. Hypophosphatasia (HPP) is a rare
inherited metabolic disease in which mutations in
the ALPL gene (encoding tissue-nonspecific
alkaline phosphatase) result in varying degrees of
enzyme deficiency. HPP manifests in a spectrum
of symptoms, including early primary tooth loss
(root intact) and alveolar bone mineralisation
defects.
Objective. To provide an overview of HPP for den-
tal professionals to help recognise and differen-
tially diagnose patients for appropriate referral to
a specialist team.
Methods. A non-systematic review of publications
on HPP was performed.
Results. Different forms of HPP are described,
along with characteristic symptoms and laboratory
findings. Diagnosis is challenging due to the rare-
ness and variable presentation of symptoms. Low
alkaline phosphatase levels are a signature of HPP,
but reference ranges vary according to gender and
age. Key features are defined and management
strategies discussed, focusing on enzyme replace-
ment therapy. Finally, a patient registry aimed at
better defining the prevalence of HPP and raising
awareness is described.
Conclusions. HPP is a rare disease with a wide
spectrum of manifestations, with orodental symp-
toms featuring prominently in the natural history.
Dental professionals may be positioned at the
beginning of the diagnostic pathway; thus, recog-
nition of HPP features for timely referral and opti-
mal disease management is important.
Introduction
Hypophosphatasia (HPP; On Line Mendelian
Inheritance in Man [OMIM] #146300,
241500, 241510) is a rare genetic disorder
with autosomal dominant and autosomal
recessive inheritance. It is characterised by a
mineralisation deficit affecting the bones and
teeth, which is associated with deficient and
reduced enzymatic activity of tissue-nonspeci-
fic alkaline phosphatase (TNSALP)1–4. Muta-
tions of the ALPL gene (1p36.1-p34), which
encodes TNSALP, are responsible for the
reduction in enzymatic activity. TNSALP is
expressed in the liver, bones, and kidneys,
and also found in the enamel, dentine,
cementum, and alveolar bone5.
In the event of reduced enzymatic activity
of TNSALP, substrates that are not broken
down (pyridoxal 50-phosphate, inorganic
pyrophosphate, and phosphoethanolamine)
build up and produce toxic effects; for exam-
ple, inorganic pyrophosphate is a powerful
mineralisation inhibitor6. These substrates
may be detected in blood and urine7–13. Six
clinical forms of HPP that relate to the age at
onset of the symptoms have been described:
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perinatal (fatal), benign prenatal, infantile,
childhood, adult, and odonto-HPP, which is
limited to orodental manifestations
(Table 1)4,11–14. Disease severity is highly
variable, but typically inversely proportional
to the age at onset of the initial symp-
toms11,14; however, in reality, the clinical pre-
sentation of the disease is more complex than
this classification suggests.
The perinatal form is the most severe and
results, in utero or at birth, in the almost total
absence of bone mineralisation11; for exam-
ple, reports are not uncommon of an almost
complete lack of mineralisation in the skull or
rib cage. The benign prenatal form can be
detected through bone-related symptoms in
the prenatal period12. Its course is more
favourable than the severe perinatal form12.
The infantile form typically develops at
around 6 months of age and results in severe
bone deformities and rickets13. It may also
present with respiratory complications, pre-
mature craniosynostosis, hypercalcaemia, and
nephrocalcinosis11. Additionally, the onset of
epileptic seizures secondary to the build-up of
pyridoxal phosphate often occurs and is a sign
generally incompatible with survival13.
The childhood form of HPP appears
>6 months and presents in very diverse
forms. Bone deformities may be minor, and
the disease may result only in the early loss
of the primary teeth13; however, in some
cases, it is associated with moderate HPP-
related rickets, short stature, delayed walking
or gait disorders, and pain in the lower
limbs11,15.
Adult HPP tends to manifest in middle age,
but there is usually history of premature loss
of primary teeth13. It involves early loss of
the permanent teeth, which is usually associ-
Table 1. Key features of the six clinical forms of hypophosphatasia4,11–14.
Form of
HPP Perinatal
Benign
prenatal Infantile Childhood Adult Odonto-HPP
Age at onset
of first
signs/
symptoms
In utero and
at birth
In utero <6 months
of age
≥6 months–
18 years of
age
≥18 years of age Any age
Clinical
signs
and
symptoms
Stillbirth
Hypomineralisation
Chest deformity
Long-bone
deformity
Osteochondral
spurs
Radiolucencies
into metaphyses
Poorly ossified
epiphyses
Fractures
Seizures
Apnoea
Skeletal
disease
(poor skeletal
mineralisation)
in utero
Foetal
crowding
Long-bone
narrowing
Benign
postnatal
course
Rickets
Fractures
Respiratory
insufficiency/
failure
Poor feeding/
weight gain
Failure-to-thrive
Hypotonia
B6-responsive
seizures
Craniosynostosis
Nephrocalcinosis
Hypercalcemia/
hypercalciuria
Rickets
Skeletal deformity
Poor healing
or recurrent
fractures
Hypomineralisation
Short stature
Muscle weakness
Missed motor
milestones
Chronic muscle/
joint/bone pain
waddling
Nephrocalcinosis
Fractures/
pseudofractures
Osteomalacia
Chondrocalcinosis
Osteoarthropathy
Pseudogout
Chronic muscle/
joint/bone pain
No abnormalities
of skeletal
system
Loss of
alveolar bone
Dental
features
N/A N/A Premature primary
tooth loss
Premature tooth
loss (incisors
often first)
History of
premature
primary tooth
loss
Adult tooth
loss
Abnormal
dentition
Early dental
exfoliation
(incisors)
Reduced
thickness of
the dentin
Enlarged pulp
chambers of
teeth
Dental caries
Inheritance AR AD AR AR (frequent)
or AD (rare)
AR or AD AR or AD
AD, autosomal dominant; AR, autosomal recessive; N/A, not applicable.
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ated with multiple fractures, osteomalacia,
chondrocalcinosis, osteoarthropathy, and
stress fractures. Some cases are associated
with a family or personal history of moderate
rickets during childhood15.
Odonto-HPP is limited to dental manifesta-
tions alone and can occur at any age13. Alve-
olar bone loss is apparent, but otherwise no
skeletal abnormalities are evident11.
HPP is a chronic, disabling disease with
multiple facets that must be taken into
account. It presents as a continuum, from
childhood to adulthood, and its clinical
expression changes over the course of the
patient’s lifetime, in particular during certain
periods (adolescence, menopause) or in
response to specific events (fractures, inges-
tion of vitamin D)13. With increasing age, the
problems of osteoarthritis, osteoporosis,
nephrocalcinosis, muscle weakness, and
repeated fractures may exacerbate the clinical
situation16.
The aim of this article was to provide an
overview of HPP with the hope of raising dis-
ease awareness and aiding its recognition and
correct management for the practicing dentist
and dental surgeon.
Epidemiology
Based on molecular tests, the prevalence of
severe HPP in Europe is estimated to be
approximately 1 case per 300,000 individu-
als17. The incidence of moderate forms is
without doubt higher than severe forms,
possibly as high as 1 in 637017; however,
at present, there are between 80 and
100 known cases of HPP in France, includ-
ing 70 patients with very severe forms
(perinatal or infantile HPP), which suggests
that these forms are largely underdiag-
nosed17. In Japan, the prevalence of severe
perinatal lethal HPP, classified according to
clinical features, is estimated to be approxi-
mately 2–3 cases per 100,000 births18 and
the incidence of the most severe forms of
HPP in Canada was estimated to be approxi-
mately 1 in 100,000, but this figure is from
a study published more than 50 years
ago19,20.
Clinical signs and characteristic symptoms
The key bone and dental manifestations of
HPP are outlined in Table 1.
Bone symptoms
Bone fragility and deformities may be present
in utero or at birth. Growth in stature and
weight gain are poor in forms of HPP that
manifest at an early age15. In childhood forms
of HPP, the patient often finds it difficult or
even impossible to walk (resulting in a limp
and the use of crutches or a wheelchair). Pain,
being late to sit up or walk, growth retarda-
tion, and muscle weakness are all warning
signs for HPP. Associated symptoms are prema-
ture craniosynostosis with intracranial hyper-
tension, plagiocephaly, or quite the opposite,
the presence of a wide fontanelle that is slow
to close, metaphyseal abnormalities, diaphy-
seal incurvation, and highly fragile bones11,15.
Dental symptoms
Early loss of primary teeth, before age 3, may
affect all teeth or just those in the incisor–
canine region. The primary teeth are shed
with their roots intact. The first sign is often
tooth mobility, which leads the patient and
their family to seek advice; subsequent radio-
graphs reveal severe alveolar bone loss15. Early
loss of primary teeth exists in all forms of HPP
and should be part of the medical/dental
history questionnaire for patients of all ages.
The clinical picture in older children and
adults with HPP generally includes the early
loss of all or some of the permanent teeth.
There may be, however, no associated skele-
tal deformities, such as in odonto-HPP15.
Such early tooth loss is not generally associ-
ated with an inflammatory and infectious
context, which, if present, are warning signs
of other general diseases21,22. Representative
images from the childhood and adult forms of
HPP are provided in Fig. 123.
Orodental repercussions of HPP are reported
in all forms of the disease, including prema-
ture loss of primary teeth in infant and child-
hood forms; and early loss of permanent
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teeth, and sometimes periodontal disease, in
adult HPP and in odonto-HPP24. The dysregu-
lation of pyrophosphate causes abnormalities
affecting the formation of the cementum cov-
ering the tooth root, which is essential for
tooth structure and attachment to the alveo-
lar bone25, thereby contributing to early tooth
exfoliation. Problems with the formation of
dentine and amelogenesis also occur26. In
children with HPP, hypercalcaemia may result
in a poor appetite and eating problems, and
severe dental caries4. Therefore, the dental
surgeon is frequently one of the first health-
care professionals in a position to recognise
the diagnosis of HPP, in particular in older
children and adults with early unexplained
orodental issues.
Differential diagnosis
Dental considerations
Early tooth loss can also occur in immune defi-
ciencies associated with cyclic neutropenia
(a disruption in granulopoiesis resulting in
oscillations of available blood cells)27, Papillon-
Lefevre syndrome (characterised by diffuse
palmoplantar keratoderma and aggressive
periodontitis)28, Haim-Munk syndrome (char-
acterised by hyperkeratosis and erythema)29,
Chediak-Higashi syndrome (characterised by
recurrent infections and periodontal disease)30
or as part of Ehlers-Danlos syndrome (VIII,
IV; characterised by skin hyperextensibility,
delayed wound healing, and other signs)31,
or even aggressive periodontal disease32.
Dentinogenesis imperfecta occurs in about
50% of patients with osteogenesis imperfecta
and is characterised by transparent, dis-
coloured, and easily fractured fragile teeth33.
Certain dentin dysplasias can also lead to early
tooth loss34.
Medical considerations
The differential diagnosis of HPP depends on
the age at which the diagnosis is considered
and is made by considering this together
with any associated bone disorder. For
example, in the antenatal period, osteogene-
sis imperfecta is the main differential diagno-
sis; just after birth, the differential diagnosis
is based on other causes of hypercalcaemia35;
in childhood, the clinical and radiologic pre-
(a)
(d) (e)
(b) (c)
Fig. 1. (a–c) Early loss of primary teeth (83, 82, 81, 71, 72, 73) in a 30-month-old patient with a juvenile form of
hypophosphatasia with 2 heterozygous A159T mutations (c.526G>A; c.648 + 1G>A). 71 and 81 were lost at 9 months. Upper
incisors 52, 51, 61, 62 are moving. The alveolar bone has been resorbed. (d–e) Periodontal disease particularly in the anterior
region in a 27-year-old adult with a moderate infant form of HPP due to mutations of the ALPL gene in the compound
heterozygous form R119H/(G145V+Y246H). The patient’s history includes the early loss of 12 primary teeth (53, 52, 51, 61, 62,
63, 73, 72, 71, 81, 82, 83) before 3 years of age. Figure originally published in Alpha Omega News 2014;166:23–2623.
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sentation of HPP can easily be confused with
that of other forms of rickets36. The differential
diagnosis is confirmed by tests indicating
lower than normal range levels of serum
alkaline phosphatase (ALP), signs of
hypomineralisation of the bone, and/or high
or normal levels of calcium and serum phos-
phorus (Table 2)4,11,36–38,66,67.
Initial evaluation
A patient visiting a dental practice and under-
going clinical evaluation and dental treatment
on account of early tooth loss with no prior
medical diagnosis may be suffering from a
mild or moderate form of HPP (i.e., child-
hood, adult, or odonto-HPP).
Medical history
Healthcare professionals should always inves-
tigate a history of early tooth loss during
childhood in the patient and other family
members. Early destruction of the periodon-
tium, which in some cases is not associated
with an infective or inflammatory context,
movement of the teeth, or early tooth loss in
adults, may also be warning signs. Addition-
ally, the patient’s medical history should be
examined for bone problems, rickets, osteo-
malacia, fractures, osteopenia, osteoporosis,
pain, muscle weakness, and craniosynostosis.
Other clinical signs may exist, such as muscle
weakness and chronic pain, nephrocalcinosis,
hypercalciuria, respiratory failure, rheumatic
disorders (chondrocalcinosis, osteoarthropa-
thy, pseudogout), and neurological disorders
(epileptic seizures, delayed motor develop-
ment).
Clinical examination
The clinical examination will focus on assess-
ing loss of primary/permanent teeth in rela-
tion to the patient’s age. An examination of
the teeth shed, if they have been kept, may
be useful to determine whether the root is
almost intact. The mobility of remaining teeth
should be assessed together with the health
of the periodontium. Radiographs may
include a panoramic image and may also
include intraoral periapical radiographs of the
areas affected, or even assessment by cone
beam computed tomography (CBCT). The
assessments will vary according to the
patient’s age and relevant guidelines for
the appropriate use of radiographs in dental
care39. Whereas guidelines for appropriate
use of CBCT vary between countries40–42, it is
considered of potential benefit for conditions
involving structural or eruption anomalies of
teeth, of which HPP is a clear example.
Associated dental abnormalities such as bul-
bous crowns with cervical constriction, wide
pulp chambers, taurodontism of the molars,
short roots43, and hypoplastic enamel should
be investigated. Eruption disorders may occur
such as eruption retardation1, ankylosis of the
primary teeth, and permanent tooth retention
or impaction. These abnormalities are not
always present and depend on the severity of
the disease.
Table 2. Low alkaline phosphatase (ALP) activity and high concentrations of ALP substrates differentiate hypophosphatasia
(HPP) from other disorders and can help ensure an accurate diagnosis4,11,36–38,66,67.
Disorder
HPP
Nutritional
rickets
X-linked
hypophosphataemic rickets Osteogenesis imperfecta
ALP ↓ ↑ ↑ Normal or transiently ↓
Serum PLP ↑ – ↓ –
Calcium ↑ or normal ↓ Normal Normal
Phosphate ↑ or normal ↓ ↓ Normal
PTH ↓ or normal ↑ Normal Normal
Vitamin D Normal ↓ ↓ or normal ↓ or normal
ALP, alkaline phosphatase; PLP, pyridoxal-50-phosphate; PTH, parathyroid hormone.
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Laboratory tests
Total serum ALP activity is low in all forms of
HPP (Table 2)14. If HPP is suspected, it is nec-
essary to request tests to measure serum ALP
levels. The ranges shown below are guideli-
nes, and the results should always be consid-
ered in relation to the standards issued by the
laboratories where the tests are performed,
which may vary according to the test meth-
ods used.
1) Example guidelines of normal serum ALP
levels (male or female adults):
a) 2–4.5 units (Bondansky)44
b) 4–13 units (King Armstrong)44
c) 40–120 IU/L14,45
2) Levels should be compared against specific
gender- and age-dependent reference
scales for suspicion of HPP14,45 (Table 3).
Note that a drop in levels of ALP in the
blood is not always detectable in the first test;
several tests may be necessary in some cases.
Additionally, other conditions can lead to
low ALP levels, such as pregnancy, certain
drugs, hypothyroidism, anaemia, and coeliac
disease4.
For odonto-HPP or nonsevere forms of HPP
(childhood or adult HPP), the level of ALP
may be closer to the lower limit of normal
than in the severe perinatal and infantile
forms46. Residual enzymatic activity may,
in fact, continue, minimising clinical manifes-
tations. In principle, urine phospho-
ethanolamine tests are carried out only if
there is any doubt regarding the diagnosis;
levels are elevated in patients with HPP20.
Serum pyridoxine 50-phosphate is also
elevated and is a sensitive marker for HPP20.
This assessment in children may then be com-
pleted by an analysis of the following param-
eters: calcium, phosphate, parathyroid
hormone, and vitamin D. Radiographs of the
left hand and one knee will allow a metaphy-
seal assessment. These tests will also aid dif-
ferential diagnosis and rule out other causes
of rickets (Table 2)11.
A medical referral is one of the initial steps
that should be taken by a dental health pro-
fessional when a diagnosis of HPP is consid-
ered. If HPP is suspected, it may be necessary
to pursue an accurate diagnosis by sequenc-
ing the defective gene. If there is any doubt,
it is absolutely essential to refer the patient
and his/her family to a paediatrician, geneti-
cist, and a reference/specialist centre.
Genetic diagnosis
A diagnosis of HPP is made on the basis of
the clinical symptoms supported by the
results of laboratory tests, that is a low serum
ALP level that requires further biological
studies and analysis of the ALPL gene4,47. A
genetic consultation is recommended prior to
the molecular test. A prenatal genetic diagno-
sis is possible for families who already have a
clinical and molecular diagnosis.
Management
The early loss of primary and/or permanent
teeth is almost always a warning sign of a
more general illness, and special attention
should be paid to the investigation of associ-
ated signs. This finding should be reported to
the physician in charge of the child or adult
patient (paediatrician, general practitioner,
geneticist, etc.). This medical diagnosis, sup-
ported by the observations of the dental sur-
geon, is important for the child and his/her
family.
Specialist centres
A variety of rare disease resources are avail-
able to patients worldwide, including several
reference centres for rare diseases (Table 4)48.
Within Europe, the identification, number,
Table 3. Age- and gender-dependent scales for suspicion of
hypophosphatasia14,45.
Age range (years)
Serum ALP level for suspicion of
HPP
Males (IU/L) Females (IU/L)
1–3 ≤125 ≤125
4–11 ≤150 ≤150
12–13 ≤160 ≤110
14–15 ≤130 ≤55
16–19 ≤60 ≤40
≥20 ≤40 ≤40
ALP, alkaline phosphatase; IU/L, international units per litre.
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and distribution of rare disease reference cen-
tres vary by member country, along with the
services provided49,50. Generally, these cen-
tres aim to provide countrywide coverage
with management structures and named
competence centres. They operate in partner-
ship with specialist centres and in collabora-
tion with practitioners in the private sector
and highly-skilled local healthcare providers.
They are able to guide the dentist or dental
surgeon in diagnosis and provide advice on
the management and follow-up of these
patients. Long-term management is also
offered in specialist dental centres, including
making paediatric prostheses when the
patient is 2.5–3 years of age to compensate
for the loss of the primary teeth and manag-
ing prosthetic implants in the adult patient51.
Orthodontic follow-up may be indicated,
bearing in mind that treatment should be
given with caution on account of the
health of the periodontium. Other reference
centres/specialist centres that focus on rare
calcium and phosphorus disorders and bone
Table 4. Reference centres dealing with different aspects of hypophosphatasia48,68.
Region Country Centre locations
Europe Austria Salzburg
Belgium Leuven
Bulgaria Sofia
Cyprus Nicosia
Denmark Aarhus, Copenhagen
Estonia Tartu
France Amiens, Bordeaux, Brest, Caen, Cayenne, Clermont-Ferrand, Dijon, Le Mans, Lille, Limoges, Lyon,
Marseille, Montpellier, Nancy, Nantes, Nice, Nimes, Paris, Pointe a Pitre, Poitiers, Reims, Rennes,
Reunion, Rouen, Saint-Denis, Saint-Etienne, Saint-Laurent-du-Maroni, Strasbourg, Toulon,
Toulouse, Tours, Vandoeuvre-Les-Nancy, Vannes
Germany Aachen, Berlin, Bonn, Datteln, D€usseldorf, Essen, Freiburg, Hamburg, Hannover, Heidelberg,
K€oln, Munich, W€urzburg
Hungary Pecs
Italy Acquaviva delle Fonti, Avellino, Belluno, Benevento, Bologna, Cagliari, Campobasso, Catania,
Catanzaro, Chieti, Dolo, Florence, Genoa, Imola, Milan, Monza, Naples, Padova, Palermo,
Perugia, Pievesestina di Cesena, Pisa, Ragusa, Reggio Emilia, Riga, Rome, Rotondo, Ruffano,
San Giovanni Salerno, Siena, Trento, Trieste, Troina, Turin, Udine, Verbania, Verona
Lebanon Beirut
Lithuania Vilnius
Morocco Fes, Rabat
Netherlands Amsterdam
Norway Oslo
Portugal Coimbra, Lisbon, Porto, Vila Real
Romania Sibiu
Russia Moscow
Slovenia Ljubljana
Spain Badajoz, Barcelona, Caceres, El Palmar, Madrid, Santander, Seville, Valencia
Sweden Stockholm, Uppsala
Switzerland Lausanne
Turkey Ankara, Istanbul
United Kingdom Manchester, Sheffield
Middle East
and Africa
Abu Dhabi Al-Ain
Saudi Arabia Riyadh
South Africa Randburg
North America Canada Montreal, Sherbrooke, Toronto, Winnipeg
USA Austin, TX; Chicago, IL; Durham, NC; Indianapolis, IN; Los Angeles, CA; Milwaukee, WI; Nashville,
TN; Portland, OR; St. Louis, MO; Durham, NC; Atlanta, GA; Omaha, NE; Houston, TX; Cincinnati,
OH; Pittsburgh, PA
Asia Pacific Australia Victoria
Japan Osaka
Taiwan Taipei
South America Brazil S~ao Paulo
Reference centre locations may be identified by visiting http://www.orpha.net/consor/cgi-bin/index.php48.
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diseases, working as partners (Table 4), can
provide support for the patient’s medical
management.
Treatment
At the time of preparation of this manuscript,
the enzyme replacement therapy asfotase alfa
(StrensiqTM; Alexion Pharmaceuticals Inc, New
Haven, CT, USA) is the only available
treatment for HPP52. It is approved for the
treatment of perinatal/infantile- and juvenile-
onset HPP in the USA53, Canada54, and Eur-
ope55, and for the treatment of HPP in
Japan56. Asfotase alfa is a recombinant
human TNSALP onto which an anchor has
been grafted to allow it to affix to the
bone57,58. This treatment has been tested in a
mouse model of HPP with promising
results57,59, in particular in relation to bone
mineralisation and the almost total disappear-
ance of orodental signs associated with the
disease60,61. Spectacular improvements in
terms of survival, skeletal manifestation (in-
cluding healing of rickets), pulmonary func-
tion, and growth were reported when
asfotase alfa was studied in young children
with very severe perinatal or infantile HPP58.
Other treatments, such as other enzyme
replacement therapy or even gene therapy,
have also been investigated in animal
models62,63.
Treatment of comorbidities associated with
HPP is also important11; however, it must be
noted that some treatments suitable for bone
conditions such as rickets and osteomalacia
(high-dose vitamin D, calcium supplements,
bisphosphonates) may exacerbate the symp-
toms of HPP and cause additional problems,
such as hypercalcaemia, and should be
avoided11,64.
The importance of setting up a registry
The exact prevalence of HPP is not known, par-
ticularly that of the odonto-HPP form. The den-
tist/dental surgeon can contribute to a better
understanding of this dental anomaly and asso-
ciated rare diseases by registering their patients
in the HPP interactive biomedical database,
D[4] (Diagnosing Dental Defects Database)/
PHENODENT (www.phenodent.org, Stras-
bourg Cedex, France). On 11 September 2001,
the Comite Consultatif sur le traitement de l’Infor-
mation en matiere de recherche dans le domaine de
la Sante (CCTIRS), a French consultative com-
mittee on data processing in health research,
issued a favourable opinion of this registry,
which was authorised on 18 May 2009 by the
Commission Nationale Informatique et Libertes
(CNIL), the national commission on data pro-
cessing and protection (registration number
908416).
Global efforts are underway to set up an
international registry with the aim of provid-
ing a comprehensive, real-life, longitudinal
profile of patients with HPP (ClinicalTrials.-
gov: NCT02306720)65. Data concerning
patients’ treatment and clinical condition will
be collected as available from medical records
at registry entry (baseline) and a minimum of
every 6 months thereafter. The types of infor-
mation collected will include demographics,
HPP disease history and diagnosis, HPP clini-
cal history at baseline, genotypes, biochemi-
cal, laboratory and radiologic phenotypes,
disease status at follow-up visits, and patient-
reported outcomes (such as quality of life,
pain/symptoms, and physical function) at
baseline and follow-up visits. Patient confi-
dentiality will be maintained throughout. As
of 1 June 2015, eight patients have been
enrolled. Three sites are active in two coun-
tries (the USA and the UK), and sites in eight
additional countries are in the process of
being activated in anticipation of starting the
broader phase of the study (France, Germany,
Spain, Russia, Czech Republic, Austria, Bel-
gium, and Italy).
This special effort is being made to register
patients affected by any form of HPP because
of the development of pharmaceutical treat-
ments including enzyme replacement therapy.
Analysis of information gathered by the HPP
registry study will lead to a better understand-
ing of HPP which, in turn, will increase aware-
ness, aid diagnosis, and improve patient care.
Identification of a cohort
Registration of patients with HPP in the reg-
istry will make it possible to create an HPP
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cohort. This is a real benefit for patients with
HPP who may not currently benefit from a
specialist opinion covering all aspects of their
condition as part of their treatment plan.
Creating a cohort will inevitably enhance
patient management and lead to a follow-up
system that is not fragmented, but which is
also in harmony with the different aspects of
management that will be needed throughout
the patient’s life.
Recording of the natural history of the disease
It is important to characterise the process of
the disease, to understand its variable presen-
tation, and identify markers of disease pro-
gression. Such information is essential to the
selection of patients who might benefit from
treatment and for the evaluation of the effi-
cacy of any treatment. Although various ther-
apeutic approaches are being developed, it is
possible that not all patients will be suitable
for the same medication or the same treat-
ment regimen. A better understanding of
patients and a clearer picture of their condi-
tion will make it easier to select the medica-
tion to be administered.
Development of a specific database
It is necessary to collect precise information on
different aspects of HPP and to have a single
tool for recording information such as geno-
type (type of genetic defect), phenotype
(whether bone or teeth related), the course of
the disease, any treatment that may have been
given, and quality of life. Currently, these data
are fragmented for each individual patient;
they may be collected in some cases, but gen-
erally focus on one specific problem or area.
The idea of such a database is to allow infor-
mation to be shared between specialists in all
areas of HPP (e.g., growth, metabolism of
bone, phosphorus and calcium, genetics, oral
cavity, pain). A quality-of-life module and the
ability to include data provided by patients are
very important for assessment of the impact of
the disease and its course.
Often, healthcare professionals may only be
able to focus on their area of expertise, possi-
bly due to various constraints in healthcare
systems, and may not have access to informa-
tion and resources on other aspects of the dis-
ease. As a result, they might not be able to
provide a holistic approach to the manage-
ment of HPP, and different specialties may
need to be involved in the care of different
manifestations of the disease. For the health-
care professional, therefore, the ability to
access all the patient’s data in a central reg-
istry will be extremely important. Orodental
issues are closely linked to disease severity;
therefore, this information is important to
share.
Limited data are available on the course of
the disease in HPP, hence the importance of
patient follow-up. With regard to teeth, little
information is available to allow a comparison
of primary teeth history (e.g., the number of
teeth lost) with status of the permanent teeth.
In fact, reports are generally produced and
issued at a given time, and there is no multi-
aspect, multiprofessional follow-up of patients
over time. Follow-up of this type may improve
our knowledge of the natural history of HPP
and also make it possible to identify patients
who would be candidates for treatment.
This research tool may provide a better
understanding of the disease, a better under-
standing of the link between clinical signs
(phenotype) and the genotype of this disease,
the identification of more patients, the dis-
covery of new genes behind such cases of
HPP, the identification of modifying genes,
and the evaluation of treatments.
What action should be taken if the diagnosis is
suspected or confirmed?
It is of great importance for patients and their
treating practitioners to liaise with reference
and other specialised centres to benefit from
coordinated management of HPP, from clini-
cal and molecular diagnosis to treatment and
registry participation.
HPP patient support groups worldwide help
patients and their families understand and
deal with every aspect of the disease
(Table 5). They are a source of accurate, up-
to-date information for patients, especially
with regard to treatment development and
research. These support groups may promote
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research programs, seek funding and engage
in various activities, and create educational
materials to help increase knowledge and
awareness of HPP.
Further information
Further information can be obtained from
Orphanet, the European portal for rare dis-
eases and orphan drugs, sections on HPP
www.orpha.net, www.hypophosphatasia.com,
and OMIM (http://www.ncbi.nlm.nih.gov/
omim) numbers 146300, 241510, and
241500.
Prof. Etienne Mornet maintains a database of
known ALPL gene mutations at http://www.
sesep.uvsq.fr/03_hypo_mutations.php. As of
6 October 2015, a total of 300 mutations have
been described.
Conclusions
In a patient presenting with unexplained pre-
mature primary and/or permanent tooth loss,
the dental surgeon, and especially the paedi-
atric dentist, is at the heart of the challenges
associated with the diagnosis, management,
and follow-up of patients with HPP. Dental
surgeons must play an active part in national
and international initiatives to identify
patients with HPP through their participation
and inclusion in a rare diseases register. This
voluntary action will support enhanced
knowledge and evidence-based orodental
medicine.
Why this paper is important to paediatric dentists
 Dentists and dental surgeons can play an active part
in initiatives to identify patients with HPP through
their participation in a rare disease registry
 This voluntary action will support efforts to enhance
knowledge of and obtain evidence-based data relating
to HPP in orodental medicine
 Early identification of patients can improve access to
life-changing therapy
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Table 5. Hypophosphatasia Patient Support Groups.
Name Contact Information Activities
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Europe
16 rue Barbanegre 68330 –
Huningue, France
contact@hypophosphatasia.eu
www.hypophosphatasia.eu
Established in 2004, the group brings together patients and families,
healthcare professionals and the general public with an interest in
HPP in many projects and initiatives
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Foundation
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Boonton, New Jersey 07005, USA
+1 973 453 3093
+1 866 827 9937
http://softbones.org/
Provides information, education and support for people with HPP,
their families and caregivers; promotes research of the disease
through awareness and fundraising efforts
Hypophosphatasie
Deutschland e.V
Rottendorfer Straße 1,
97072 W€urzburg, Germany
+49 0931 782937
http://www.hpp-ev.de
Provides comprehensive awareness of symptoms and problems of
patients with HPP to the general public and medical professionals.
Assists affected families by providing a forum for the exchange of
experiences and discovery of the latest research, as well as direct
assistance in times of crisis. The association implements new
research projects into HPP and its treatment
HPP-Choose Hope 8429 Indigo Sky Ave,
Las Vegas, NV 89129
+1 855 477 7273
info@hppchoosehope.org
http://hppchoosehope.org/
Raises funds through the HPP-Choose Hope Foundation for research
into treatments and a cure for HPP, and provides education to
physicians and families about HPP
HypoPhosPhatasia
Support Association
of Japan (HPPSA-J)
http://hypophosphatasia.life.coocan.jp/ Supports interaction and information exchange between HPP patients
and families via a message board and mailings exclusively for
association members. Information on causes of HPP, symptoms,
treatment methods and the latest research developments is also
posted. HPPSA-J conducts activities to raise awareness of HPP, and
is working towards designating HPP as a specified chronic childhood
disease and specified disease (classification of the Japanese government)
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